These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8990347)

  • 21. Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance.
    Li W; Lu L; Wang Z; Wang L; Fung JJ; Thomson AW; Qian S
    J Immunol; 2001 May; 166(9):5619-28. PubMed ID: 11313402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The donor cell type controls anti-hapten (fluorescein isothiocyanate) primary antibody response to hapten-modified syngeneic cells.
    Suzuki K; Nakashima I; Takashi M; Nagase F; Kato N; Isobe K; Mizoguchi K; Saito M
    Immunol Lett; 1982 Oct; 5(4):217-21. PubMed ID: 6816722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibody treatment to prolong the secondary cardiac allograft survival in alloantigen-primed mice.
    Xie B; Chen J; Wang F; Lan T; Wang Y; Xia J; Li Z; Xie Q; Huang R; Qi Z
    Scand J Immunol; 2010 May; 71(5):345-52. PubMed ID: 20500685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of CD40-CD154-mediated costimulation to an alloresponse in vivo.
    Förster E; Krenger W; Joergensen J; Hof R; Geha RS; Holländer GA
    Transplantation; 1999 May; 67(9):1284-7. PubMed ID: 10342324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.
    Brown PS; Parenteau GL; Dirbas FM; Garsia RJ; Goldman CK; Bukowski MA; Junghans RP; Queen C; Hakimi J; Benjamin WR
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2663-7. PubMed ID: 2011577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice.
    Lu Y; Xu LC; Parker N; Westrick E; Reddy JA; Vetzel M; Low PS; Leamon CP
    Mol Cancer Ther; 2006 Dec; 5(12):3258-67. PubMed ID: 17172429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin.
    Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL
    J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation.
    Cooper MM; Robbins RC; Goldman CK; Mirzadeh S; Brechbiel MW; Stone CD; Gansow OA; Clark RE; Waldmann TA
    Transplantation; 1990 Nov; 50(5):760-5. PubMed ID: 2238051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of double-negative regulatory T cells in long-term cardiac xenograft survival.
    Chen W; Ford MS; Young KJ; Cybulsky MI; Zhang L
    J Immunol; 2003 Feb; 170(4):1846-53. PubMed ID: 12574350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of cognate help by CD4+ T cells and anergy of CD8+ T cells are the principal mechanisms for anti-leukocyte function-associated antigen-1/intercellular adhesion molecule-1-induced cardiac allograft tolerance.
    Bashuda H; Seino K; Ra C; Yagita H; Okumura K
    Transplantation; 1997 Jan; 63(1):113-8. PubMed ID: 9000671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response to a hapten of fluorescein isothiocyanate in a single mouse analyzed by two-dimensional affinity electrophoresis.
    Nakamura K; Mimura Y; Takeo K
    Electrophoresis; 1993; 14(1-2):81-7. PubMed ID: 8462521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways.
    Woodward JE; Qin L; Chavin KD; Lin J; Tono T; Ding Y; Linsley PS; Bromberg JS; Baliga P
    Transplantation; 1996 Oct; 62(7):1011-8. PubMed ID: 8878397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection.
    Kirkman RL; Barrett LV; Gaulton GN; Kelley VE; Koltun WA; Schoen FJ; Ythier A; Strom TB
    Transplantation; 1985 Dec; 40(6):719-22. PubMed ID: 3934807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrathymic alloantigen-mediated, tolerant, completely major histocompatibility complex-mismatched mouse hearts are specifically rejected by adoptively transferred anti-class I L(d+)-specific 2C cells.
    Otomo N; Motoyama K; Yu S; Shimizu Y; Margenthaler J; Tu F; Flye MW
    Surgery; 2000 Aug; 128(2):206-12. PubMed ID: 10922993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of CD4(+) T helper 2-type cells in cutaneous inflammatory responses induced by fluorescein isothiocyanate.
    Dearman RJ; Kimber I
    Immunology; 2000 Dec; 101(4):442-51. PubMed ID: 11122447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor engagement on cells expressing a ligand for the tolerance-inducing molecule OX2 induces an immunoregulatory population that inhibits alloreactivity in vitro and in vivo.
    Gorczynski RM; Yu K; Clark D
    J Immunol; 2000 Nov; 165(9):4854-60. PubMed ID: 11046009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-lasting unresponsiveness to polyclonal T cell-binding immunoglobulins.
    Mysliwietz J; Thierfelder S
    Eur J Immunol; 1998 Jan; 28(1):246-56. PubMed ID: 9485204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation.
    Hancock WW; Sayegh MH; Kwok CA; Weiner HL; Carpenter CB
    Transplantation; 1993 May; 55(5):1112-8. PubMed ID: 8497891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A proteasome inhibitor effectively prevents mouse heart allograft rejection.
    Luo H; Wu Y; Qi S; Wan X; Chen H; Wu J
    Transplantation; 2001 Jul; 72(2):196-202. PubMed ID: 11477338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.